spacer
home > > summer 2002 > drug delivery technologies: innovations and market challenges - a report in the biotechnology reports series
PUBLICATIONS


Drug Delivery Technologies: Innovations and Market Challenges - A Report in The Biotechnology Reports Series

The drug delivery industry has been something of a Cinderella until recently. It is clearly appropriate that as the biotechnology industry becomes more prominent as a source of medicines - albeit typically macromolecules rather than the smaller, organic molecules of the traditional, mainstream pharmaceutical industry - this report should issue in the Biotechnology Reports series. Nevertheless, this report does pay major attention to smaller sized pharmaceutical molecules. The information contained within it is not of a highly technical nature. However, there are already many publications meeting the needs of the pharmaceutical scientist active in the area. This report addresses the non-technical needs of this and other audiences.

An introductory chapter makes the case for the importance of drug delivery in the development of both novel compounds and established products. The various advantages of drug delivery technologies are delineated, as are the various barriers which drug delivery technologies seek to address. A useful discussion of how pharmaceutical and biotechnological industry dynamics are underpinning a growth rate of 15 to 20 per cent per year in the drug delivery industry, is enhanced by useful examples such as patent extension strategies for Eli Lilly with Prozac and AstraZeneca with Losec.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
A review by Dr Roy Drucker, General Manager of Technomark Consulting Services Limited

Roy Drucker joined the European R&D arm of Sterling Drug Inc as a Medical Advisor. He was promoted to being responsible for clinical pharmacology, drug metabolism and bioanalysis in Europe. In 1986 he moved to the Upjohn Company, subsequently Pharmacia & Upjohn, Inc., where he held a range of international responsibilities. His positions there included Director of Marketing with responsibility for worldwide marketing of cardiovascular products; Executive Director, European Community Affairs and Business Systems; and Vice-President, Drug Development, with global responsibility in multiple therapeutic areas for clinical drug development and medical support for marketed products.

A graduate of the Harvard Business School Advanced Management Program, a member of the Securities Institute and an FSA registered Approved Person, Roy has been based in Belgium, the UK, and the US. He has been General Manager of Technomark since September 1996.

spacer
Roy Drucker
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck Introduces New Integrated Plug & Play Upstream Development Service

• Adaptive approach to cell line development, analytics and clone selection for emerging biotechs and start-up • Tailored upstream development from a single source reduces time to clinic by 20 percent • Fast-track process reduces timeline by 10 weeks for first pharmacodynamic experiment
More info >>

White Papers

RSSL introduces same-day mycoplasma testing service in UK

RSSL

Reading Scientific Services Ltd (RSSL), a leading provider of scientific and technical solutions to the global biopharmaceutical, pharmaceutical, and biopharmaceutical sectors, has introduced the United Kingdom’s first same-day mycoplasma testing service for manufacturers of biologic medicines.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement